Phytecs is a biotechnology company focused on harnessing the therapeutic potential of the endocannabinoid system (ECS) to develop innovative treatments for various diseases. The ECS is a complex network that plays a crucial role in regulating numerous physiological processes throughout the human body. Phytecs conducts extensive research to explore how modulating the ECS can address significant unmet medical needs. Their development pipeline includes both natural and semisynthetic compounds, with a particular emphasis on fluorinated derivatives of cannabidiol (CBD) to enhance bioavailability and therapeutic efficacy. The company is committed to advancing drug discovery through preclinical research, which has identified lead compounds that show promise in targeting specific therapeutic indications.

In addition to their focus on CBD derivatives, Phytecs is investigating the synergistic effects of various phytocannabinoids, including tetrahydrocannabinol (THC), cannabigerol (CBG), and others. This research aims to uncover the potential of these compounds in combination to produce enhanced therapeutic outcomes. Phytecs has secured patent protection for its lead fluorinated CBD variants and is actively pursuing additional claims globally. Their ongoing studies utilize in vitro and in vivo models to evaluate the efficacy of these compounds in treating conditions such as anxiety, epilepsy, and skin diseases, thereby contributing to the growing body of evidence supporting the ECS's role in therapeutic applications.

United States

Phytecs is exploring product development derived from its research conducted across the globe: North and South America, Europe and Israel. Phytecs researches compounds and derivatives from plant species to create tomorrow’s medicines. These plants produce compounds that interact with the endocannabinoid system in many different ways, from mimicking endocannabinoids to slowing or accelerating the enzymes that metabolize them.

Phytecs

Company Details